Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alpha Cognition Inc C.ACOG

Alternate Symbol(s):  ACOGF

Healthcare Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062... see more

Recent & Breaking News (CSE:ACOG)

Alpha Cognition Inc. (TSXV:ACOG) closes $14.4 million public offering

Caroline Egan  October 1, 2021

Alpha Cognition Announces Closing of $14.4 Million Public Offering

Newsfile October 1, 2021

Alpha Cognition Announces Formation and Members of Scientific Advisory Board and Investor Relations Agreements

Business Wire October 1, 2021

Today’s market update: a stumbling TSX signals caution into Q4

Trevor Abes  September 29, 2021

Alpha Cognition Extends Public Offering

John Ballem  September 29, 2021

Alpha Cognition Updates Anticipated Closing Date of Public Offering

Newsfile September 29, 2021

Top 5 Stories of the Week: Defence Therapeutics (CSE:DTC), Next Hydrogen (TSXV:NXH), XTM (CSE:PAID), PyroGenesis (TSX:PYR), and Alpha Cognition (TSXV:ACOG)

Julia Kennedy  September 24, 2021

Alpha Cognition (TSXV:ACOG) announces $12.5 million public offering

Trevor Abes  September 23, 2021

IIROC Trading Resumption - ACOG

PR Newswire September 23, 2021

Alpha Cognition Announces Pricing of Public Offering

GlobeNewswire September 23, 2021

IIROC Trading Halt - ACOG

PR Newswire September 23, 2021

Alpha Cognition Announces Overnight Marketed Offering

GlobeNewswire September 22, 2021

Alpha Cognition, Focused on Neurodegenerative Diseases, CEO Clip Video

Newsfile September 11, 2021

Alpha Cognition Announces the Acceptance of its US FDA Investigational New Drug Application (IND) for Lead Candidate, ALPHA-1062 for Mild to Moderate Alzheimer's Disease

Business Wire September 7, 2021

Alpha Cognition Reports Second Quarter of Fiscal 2021 Results

Business Wire September 3, 2021

Alpha Cognition to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Business Wire September 1, 2021

Alpha Cognition Receives Approval to Commence Trading on the OTCQB

Business Wire August 20, 2021